Amy Laysang

TL;DR: The authors targeted DLL3 with an antibody conjugated to a cytotoxic drug, which proved to be much more effective than standard chemotherapy for treating patient-derived tumor xenografts and is a promising first-in-class ADC for the treatment of high-grade pulmonary neuroendocrine tumors.

TL;DR: The results provide the first demonstration of the efficacy of nTregs pharmacologically expanded in vivo in preventing acute GVHD without abrogation of the beneficial graft-versus-leukemia effect.

TL;DR: It is demonstrated that PDX tumor models can be efficiently established from primary SCLC transbronchial needle aspirates, even after overnight shipping, and that resulting xenograft tumors are similar to matched primary tumors in cancer patients by both histology and chemo-sensitivity.

TL;DR: The synthesis of novel PNU-159682 derivatives and the subsequent linker drugs as well as the corresponding biological evaluations of the small molecules and ADCs are described.

TL;DR: Results strongly suggest that RGI-2001 promotes the expansion of donor-derived Tregs which specifically suppress T-cell responses against host alloantigens, thereby reducing the GvHD lethality of mice that survived greater than 100 days.